Literature DB >> 22083466

Penetration of doripenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers.

Bernhard Burian1, Markus Zeitlinger, Oliver Donath, Gottfried Reznicek, Robert Sauermann.   

Abstract

Sufficient antibiotic concentrations at the infection site are a prerequisite for good bacterial killing. This study was performed to determine pharmacokinetics of doripenem in soft tissues and saliva. Six healthy male volunteers received a single intravenous infusion of 500 mg doripenem over 1 h. The concentrations of doripenem were measured over 8 h in saliva, plasma, and extracellular space fluid of skeletal muscle and subcutaneous adipose tissue employing in vivo microdialysis. Unbound drug concentrations were determined using ultra-high-performance liquid chromatography-tandem mass spectrometry. Maximum concentrations of doripenem were 15.3 ± 6.0 mg/liter in plasma, 9.9 ± 2.3 mg/liter in subcutaneous adipose tissue, 6.6 ± 2.9 mg/liter in skeletal muscle, and 0.5 ± 0.2 mg/liter in saliva. Areas under the concentration-time curve (AUC) from 0 to infinity were 26.3 ± 10.1, 20.4 ± 3.8, 12.8 ± 3.0, and 1.0 ± 0.5 mg · h/liter in plasma, adipose tissue, skeletal muscle, and saliva, respectively. Ratios of AUC in adipose tissue, skeletal muscle, and saliva to those in plasma were 0.84 ± 0.28, 0.53 ± 0.19, and 0.04 ± 0.03, respectively. In all six volunteers, a threshold of ≥40% for "time above MIC," an index indicative of good antimicrobial activity, was exceeded in adipose tissue for MICs of ≤2 mg/liter and in skeletal muscle for MICs ≤1.5 mg/liter. Doripenem penetrates well into interstitial space fluid of skeletal muscle and adipose tissue, suggesting good antimicrobial activity in infected soft tissues, whereas it is detectable in relatively low concentrations in saliva.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22083466      PMCID: PMC3256072          DOI: 10.1128/AAC.05506-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients.

Authors:  Mahesh N Samtani; Robert Flamm; Koné Kaniga; Partha Nandy
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

2.  Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem.

Authors:  Sujata M Bhavnani; Jeffrey P Hammel; Brenda B Cirincione; Matthew A Wikler; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

3.  Pharmacokinetics and tissue penetration of a new carbapenem, doripenem, intravenously administered to laboratory animals.

Authors:  Toshihiko Hori; Masao Nakano; Yasuo Kimura; Kazuhisa Murakami
Journal:  In Vivo       Date:  2006 Jan-Feb       Impact factor: 2.155

4.  Characterization of peripheral-compartment kinetics of antibiotics by in vivo microdialysis in humans.

Authors:  M Müller; O Haag; T Burgdorff; A Georgopoulos; W Weninger; B Jansen; G Stanek; H Pehamberger; E Agneter; H G Eichler
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

5.  Pharmacokinetic/pharmacodynamic modeling and simulation to determine effective dosage regimens for doripenem.

Authors:  Takayuki Katsube; Yoshitaka Yano; Toshihiro Wajima; Yoshinori Yamano; Mikihisa Takano
Journal:  J Pharm Sci       Date:  2010-05       Impact factor: 3.534

6.  Application of microdialysis to clinical pharmacokinetics in humans.

Authors:  M Müller; R Schmid; A Georgopoulos; A Buxbaum; C Wasicek; H G Eichler
Journal:  Clin Pharmacol Ther       Date:  1995-04       Impact factor: 6.875

7.  Pharmacodynamic assessment of doripenem in peritoneal fluid against Gram-negative organisms: use of population pharmacokinetic modeling and Monte Carlo simulation.

Authors:  Kazuro Ikawa; Norifumi Morikawa; Kayo Ikeda; Hiroki Ohge; Taijiro Sueda
Journal:  Diagn Microbiol Infect Dis       Date:  2008-08-13       Impact factor: 2.803

8.  Pharmacokinetic-pharmacodynamic modeling to support doripenem dose regimen optimization for critically ill patients.

Authors:  Scott A Van Wart; David R Andes; Paul G Ambrose; Sujata M Bhavnani
Journal:  Diagn Microbiol Infect Dis       Date:  2009-02-26       Impact factor: 2.803

Review 9.  Doripenem.

Authors:  David L Paterson; Daryl D Depestel
Journal:  Clin Infect Dis       Date:  2009-07-15       Impact factor: 9.079

10.  Characteristics of doripenem: a new broad-spectrum antibiotic.

Authors:  Francisco Alvarez-Lerma; Santiago Grau; Olivia Ferrández
Journal:  Drug Des Devel Ther       Date:  2009-09-21       Impact factor: 4.162

View more
  6 in total

Review 1.  Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents.

Authors:  Daniel Gonzalez; Stephan Schmidt; Hartmut Derendorf
Journal:  Clin Microbiol Rev       Date:  2013-04       Impact factor: 26.132

Review 2.  A comprehensive review on the pharmacokinetics of antibiotics in interstitial fluid spaces in humans: implications on dosing and clinical pharmacokinetic monitoring.

Authors:  Tony K L Kiang; Urs O Häfeli; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2014-08       Impact factor: 6.447

Review 3.  Mass spectrometry for therapeutic drug monitoring of anti-tuberculosis drugs.

Authors:  Johanna Kuhlin; Marieke G G Sturkenboom; Samiksha Ghimire; Ioana Margineanu; Simone H J van den Elsen; Noviana Simbar; Onno W Akkerman; Erwin M Jongedijk; Remco A Koster; Judith Bruchfeld; Daan J Touw; Jan-Willem C Alffenaar
Journal:  Clin Mass Spectrom       Date:  2018-10-19

Review 4.  A Qualitative Review on the Pharmacokinetics of Antibiotics in Saliva: Implications on Clinical Pharmacokinetic Monitoring in Humans.

Authors:  Tony K L Kiang; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2016-03       Impact factor: 6.447

5.  Microdosing as a Potential Tool to Enhance Clinical Development of Novel Antibiotics: A Tissue and Plasma PK Feasibility Study with Ciprofloxacin.

Authors:  Zoe Oesterreicher; Sabine Eberl; Beatrix Wulkersdorfer; Peter Matzneller; Claudia Eder; Esther van Duijn; Wouter H J Vaes; Birgit Reiter; Thomas Stimpfl; Walter Jäger; Alina Nussbaumer-Proell; Daniela Marhofer; Peter Marhofer; Oliver Langer; Markus Zeitlinger
Journal:  Clin Pharmacokinet       Date:  2022-01-07       Impact factor: 5.577

6.  Pharmacokinetics of Doripenem in Healthy Koreans and Monte Carlo Simulations to Explore Optimal Dosage Regimens in Patients With Normal and Enhanced Renal Function.

Authors:  So Won Kim; Sangmin Choe; Dong Jin Kim; Dae Young Zang; Dong-Hwan Lee
Journal:  Ther Drug Monit       Date:  2018-08       Impact factor: 3.681

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.